Lantheus to acquire a minority stake in Perspective Therapeutics for $33m.

Lantheus, a radiopharmaceutical-focused company, agreed to acquire a minority stake in Perspective Therapeutics, a diversified medical technology and radiopharmaceutical company, for $33m. “This collaboration with Lantheus, a leader in the radiopharmaceutical space, marks a significant milestone in advancing treatment options for various cancers, bringing us closer to more effective and targeted interventions,” Thijs Spoor, Perspective Therapeutics CEO.